THE ABORTION PILL

Mifepristone works by blocking the hormone progesterone, which is essential for maintaining a pregnancy. When progesterone is blocked, the uterine lining breaks down, the cervix softens and opens, and the baby is expelled from the mother's body. This is not a natural miscarriage—it is a chemically induced killing of an unborn child.

The drug is typically followed by misoprostol, which causes painful cramping and bleeding as the body expels the child. Women are often left to undergo this process alone in their bathrooms, isolated from any support, while their unborn children die inside them.

Since its approval in 2000, mifepristone has been associated with 151 documented deaths in the United States according to FDA adverse event reports, along with over 7,600 adverse event reports filed with the agency. These numbers include severe complications such as hemorrhage, infection, and incomplete abortion requiring surgical intervention, as well as long-term physical and psychological trauma for thousands of women.

The FDA's own data reveals that deaths from mifepristone are four times higher than the agency initially acknowledged.

A landmark 2025 study by the Ethics & Public Policy Center analyzed insurance claims data from 865,727 prescribed mifepristone abortions between 2017 and 2023—the largest real-world study of the drug to date. The findings were alarming: 10.93% of women experienced serious adverse events within 45 days, including sepsis, severe infection, and life-threatening hemorrhaging. Additionally, at least 5.26% of women required a second abortion attempt within 45 days because the first failed, exposing them to repeated trauma and additional medical risks.

These real-world outcomes starkly contrast with the controlled clinical trials that formed the basis of FDA approval, revealing a far more dangerous profile than originally reported.

Mifepristone (RU-486) is administered in a two-part oral regimen.

Where the Lord’s Supper declares, “This is my body, given for you,” the abortion industry declares, “This is my body, my choice.” Jesus’ body was offered in love—His innocent blood poured out to purchase our salvation. The unborn child’s body and innocent blood is poured out as a demonic sacrifice to fuel the enemies of Yahweh.

RU-486 perverts the sacred act of communion into something unholy.

Christ’s body brings life—the abortion pill brings death.

The Eucharist unites us to God and to one another. Mifepristone isolates women in their bathrooms, alone with their dying children.

Communion is a covenant of life and sacrifice. The two pills of medical abortion are a covenant of death and abandonment.

This is not merely a medical procedure. It is a demonic counterfeit—a dark forgery of communion. The first pill kills the body, then the second pill produces the flow of blood. It is the opposite of the bread (“This is my body”) and the wine (“This is my blood”).

The creator of life is replaced by the destroyer, and the table of blessing becomes an altar of death.

From Nazi Gas Chambers to American Bathrooms

The development of mifepristone carries a horrifying historical lineage. The drug was originally developed by the French pharmaceutical company Roussel Uclaf in the 1980s.

In 1997, Roussel Uclaf was acquired by Hoechst AG, a German chemical conglomerate. Hoechst AG was the legal successor to IG Farben, the chemical consortium that manufactured Zyklon B—the cyanide-based poison gas used by Nazi Germany to murder approximately 1.1 million people in gas chambers at Auschwitz-Birkenau, Majdanek, and other extermination camps during the Holocaust.

The same company that chemically enabled the Holocaust of WWII, is enabling the modern day holocaust of the pre-born.

The FDA first approved mifepristone (Mifeprex) on September 28, 2000, for killing the child through the first 49 days or seven weeks gestation. This initial approval came with strict requirements including in-person dispensing at clinics or hospitals, physician supervision, limited gestational age, and mandatory follow-up visits. In 2016, the FDA expanded the approved gestational limit from seven weeks to ten weeks or 70 days, increasing the number of annual deaths with the drug. On April 11, 2019, the FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, which included certification requirements for prescribers, dispensing restrictions, and patient monitoring protocols.

However, on January 3, 2023, the FDA made a controversial decision to relax the REMS requirements. The agency eliminated the in-person dispensing requirement, allowed mail-order distribution, reduced physician supervision requirements, and expanded access to abortion pills through telehealth. This deregulation opened the floodgates for mail-order abortion pills, allowing death on delivery to doorsteps across all 50 states.

Hear, O women, the word of the Lord,
and let your ear receive the word of his mouth;
teach to your daughters a lament,
and each to her neighbor a dirge.
For death has come up into our windows;
it has entered our palaces,
cutting off the children from the streets
and the young men from the squares.
(Jeremiah 9:20-21)

Death has come into our homes too—through our mailboxes!